Study Reveals Hidden Power of Sharing Cute Animal Pics
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
From clumsy puppies to grinning chimps, adorable animal content is fantastically popular on social media. But while these charming snaps are a source of instant joy for viewers, it turns out that their impact goes beyond just entertainment.
A study from Concordia University has concluded that sharing cute animal pictures online strengthens digital connections, reinforcing bonds both within social groups and online communities.
The researchers compare the act of sharing animal content on social media to "pebbling," a behavior often observed in penguins to show that they care about each other.
The penguins offer pebbles, which serve as nesting material in the barren Antarctic, to their chosen mates as a way to acknowledge their relationship and affirm their commitment to each other.
A stock image shows a person taking a picture of a stray cat with a digital camera, as the animal poses in front of them.
A stock image shows a person taking a picture of a stray cat with a digital camera, as the animal poses in front of them.
getty images
Sharing cute animal content with your friends and family serves a similar purpose, maintaining and nurturing relationships in a digital space.
After all, about 50 percent of global social media users do say that their main reason for being on social media is to keep in touch with their loved ones.
The study outlines a framework that explains the content's journey from creation to circulation. The first step is "indexicalization", the process of taking an image, gif or video of an animal, and adding an emotional cue or meaning to it, like a hashtag or a caption, to signify one's relationship with it.
Next comes re-indexicalization, when the content is shared and interacted with in what is dubbed a "techno-affective encounter". This adds new emotional layers to the media that create a shared understanding of its meaning exclusively within the group to whom it is shared.
The final step is decontextualization, when the content is stripped of personalized information and shaped into widely relatable content, like memes, to appeal to a broader audience.
"Our findings imply that companion animals' capacities as social lubricants traverse to digital space, thus facilitating interactions and reinforcing relationships as companion species content", the researchers wrote in their study.
Although this specific study only focuses on cute animal content, the researchers suggest that the same principles are likely to apply to other similar types of digital content, like food images or posts featuring funny kids.
Do you have a tip on a science story that Newsweek should be covering? Do you have a question about how we connect? Let us know via science@newsweek.com.
Reference
Shamayleh, G., & Arsel, Z. (2025). Digital Affective Encounters: The Relational Role of Content Circulation on Social Media. Journal of Consumer Research. https://doi.org/10.1093/jcr/ucaf023
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale
AI heart failure diagnostics innovator makes it possible to catch deadly heart failure earlier by analyzing the most common heart scan in the world and proactively alerting clinicians FDA-cleared, reimbursed by Medicare, and live in top U.S. hospitals, Ultromics is now scaling nationwide to make early heart failure detection part of routine cardiac care, wherever patients get an echo Ultromics is trained on one of the largest real-world echo datasets globally and validated across 25 peer-reviewed studies, helping close one of medicine's most dangerous diagnostic gaps, where up to 64% of heart failure cases still go undetected OXFORD, England, July 31, 2025 /PRNewswire/ -- Ultromics, a pioneer in AI-driven cardiology solutions, today announced it has raised $55 million in Series C financing. The round was co-led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University. Major U.S. health systems, including UChicago Medicine's venture investment vehicle, UCM Ventures, and UPMC Enterprises also participated in the round. Built on years of clinical study and hundreds of thousands of echo scans, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect HFpEF and cardiac amyloidosis, two of the most elusive forms of heart failure. The company is now expanding across the U.S. to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup. Ultromics is also expanding its pipeline to include additional cardiac conditions, new distribution channels and deeper partnerships with health systems and clinical leaders. It's a critical moment for cardiovascular care. Heart failure is rising, costs are mounting and millions of patients are still going undiagnosed, especially those with harder-to-detect forms like HFpEF and cardiac amyloidosis. In the U.S. alone, heart failure drives over $30 billion in annual healthcare costs, a number projected to exceed $70 billion by 2030. Clinicians often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses even when patients are actively seeking care. In fact, up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or irreversible damage occurs. Ultromics addresses this diagnostic blind spot by using AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions—without requiring new hardware or disrupting clinical workflows. Its FDA-cleared EchoGo® platform supports diagnosis of HFpEF and cardiac amyloidosis. Trained and validated on one of the largest real-world echo datasets globally, EchoGo® generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo® is fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide. "The reality is, hospitals already have the data, they just haven't had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we're helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses," said Ross Upton, PhD, CEO and Founder, Ultromics. "We've spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis." Ultromics has already analyzed more than 430,000 echocardiograms to date. In clinical studies, EchoGo® improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The company's latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing disease from similar conditions. "Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies," said Alastair Stewart, Head of Investments, Venture Capital, at L&G. "This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year." With growing adoption and partnerships across flagship institutions, including UChicago Medicine, University Hospitals Cleveland, Northwestern, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the Midwest. Its platform is helping hospitals reduce unnecessary tests, streamline workflows and initiate treatment earlier so it's more effective and less expensive. "Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care," said Umur Hursever, Partner at Lightrock. "Ultromics' AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics' mission and growing impact." Ultromics has rapidly expanded its platform capabilities and U.S. market presence during the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed in 2025 by the launch of EchoGo® Score, a new feature that adds AI-driven probability scoring to EchoGo® Heart Failure, helping clinicians detect HFpEF with greater nuance. These clinical advances are now supported by Medicare reimbursement for both outpatient and inpatient use, strengthening Ultromics' foundation for scaled adoption across U.S. hospitals. "There's a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret," said Victor Westerlind, Managing Director at Allegis Capital. "What's exciting about Ultromics is how they're closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it's a diagnostic win that will help save lives." About Ultromics Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately—using nothing more than a standard ultrasound scan. Ultromics is backed by leading investors and U.S. healthcare systems and is on a mission to transform how heart disease is diagnosed and treated. For more, visit About Lightrock Lightrock is a global investment platform committed to building a sustainable future. Operating across private and public markets, Lightrock manages over $5.5 billion in assets and invests in Europe, North America, Latin America, Asia, and Africa. Lightrock is a certified B Corp with a dedicated team of over 130 professionals working across a network of six offices For more information, visit About L&G Established in 1836, L&G is one of the UK's leading financial services groups and a major global investor, with £1.1 trillion in total assets under management (as at FY24) of which c. 44% (c. £0.5 trillion) is international. We have a highly synergistic business model, which continues to drive strong returns. We are a leading player in Institutional Retirement, in Retail Savings and Protection, and in Asset Management through both public and private markets. Across the Group, we are committed to responsible investing and dedicated to serving the long-term savings and investment needs of customers and society. About Allegis Capital Allegis Capital is an early-stage venture capital firm partnering with companies that enable digital transformation across the enterprise. The firm supports founders with hands-on guidance, operational expertise, and access to a global network of industry leaders. With a long track record of building market-defining businesses, Allegis backs the teams and platforms reshaping how work gets done. Headquartered in Palo Alto, California, Allegis has been investing in enterprise innovation for over two decades. For more information, visit Photo - - View original content to download multimedia: SOURCE Ultromics Sign in to access your portfolio
Newsweek
16 hours ago
- Newsweek
Map Shows States Where Tarantulas Are Roaming for Mating Season
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. It's almost tarantula mating season, and in certain states, tens of thousands of tarantulas are expected to crawl out of their burrows to look for mates. Whether you're an arachnophobe or an arachnophile, here's what you need to know about tarantula mating season and the states where the eight-legged creatures can be found. Why It Matters Tarantula mating season typically takes place from late August to October. High temperatures and moisture drive the creatures from their burrows, and males go out to search for partners. While tarantulas in the U.S. are generally not aggressive or harmful to humans, public portrayals of the large spiders—which generally measure about 4 inches or more—may inspire fear in some. Knowing more about the creatures could help relieve those concerns. Which States Have Tarantulas? According to the World Population Review, tarantulas are present in these 13 U.S. states: Arizona Arkansas California Colorado Florida Kansas Louisiana Missouri Nevada New Mexico Oklahoma Texas Utah Generally speaking, tarantulas prefer dry climates and live in Western and Southwestern states. However, they can be found in other states, and their location can depend on the species of tarantula. What Kinds of Tarantulas Are in the U.S.? The U.S. is home to about 29 species of tarantula, which primarily belong to the Theraphosidae family. Here are some of the tarantulas that can be found in the country: Aphonopelma hentzi—Texas brown tarantula. This is one of the most common species in the U.S. It is found in multiple states and reaches a 4- to 5-inch leg span. Aphonopelma chalcodes—desert blonde tarantula. Native to Arizona, this tarantula inhabits desert regions and is known for its long life span. Aphonopelma iodius—Great Basin blonde tarantula. Found in the California, Nevada and Utah deserts, females of this species can live for more than 30 years in captivity. Aphonopelma anax—Texas tan tarantula. This species is native to southern Texas and northern Mexico, and it is one of the largest species in the U.S., reaching a 5- to 6-inch leg span. Generally, tarantulas that are seen out and about are males as females are "homebodies who don't travel far from their individual burrows," according to the National Park Service. Females live longer than males, sometimes up to 25 years while males live up to 10 years. This is partly because of males going on their mating journeys and encountering danger on the way. A tarantula walks at El Impenetrable National Park, Chaco province, Argentina, on October 28, 2022. A tarantula walks at El Impenetrable National Park, Chaco province, Argentina, on October 28, 2022. LUIS ROBAYO/AFP via Getty Images Are Tarantulas Dangerous to People? According to the National Park Service, tarantulas are not aggressive or deadly, despite portrayals in pop culture. The service describes them as docile, adding that though they are capable of biting a person, this mostly happens if they are harassed, and bites are rare. Additionally, their venom is not considered to be toxic to humans. What Happens Next The mating season is set to last until the fall. According to World Population Review, "if you see a tarantula in your home, you should not kill it. Keep in mind that tarantulas are going to kill a lot of the most common pests that you might find in your home." The data site added, "If you feel like you can do so safely, try to catch it in a container. Then, release it in the wild."
Newsweek
16 hours ago
- Newsweek
Respiratory Viruses Risk Waking Dormant Cancer
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Respiratory infections like COVID-19 and the flu may increase the risk of dormant breast cancer cells reactivating and spreading in those with a history of the disease. This is the conclusion of a study based on experiments with mice and observational human health data by researchers at the University of Colorado, the Montefiore Einstein Comprehensive Cancer Center (MECCC) in New York and Utrecht University. Such an awakening, the team warn, could trigger new metastatic tumors. "Dormant cancer cells are like the embers left in an abandoned campfire—and respiratory viruses are like a strong wind that reignites the flames," said paper author James DeGregori of the University of Colorado Cancer Center in a statement. The findings highlight the need for patients to be aware of the risk between infection and cancer spread. For affected patients, "The simplest strategy would be to avoid infection (vaccination, avoiding crowded places during flu season, etc)," DeGregori told Newsweek. An illustration of cancer cells marked with green, and the proliferation of cells marked in magenta. An illustration of cancer cells marked with green, and the proliferation of cells marked in magenta. Michael DeGregori Breast cancer is the most common cancer in women. Around 316,950 new cases of invasive breast cancer will be diagnosed in women in the U.S. this year, with more than 42,000 women expected to die from the disease this year alone, according to the American Cancer Society. After remission, cancer cells may remain dormant for years before spreading— notably in the lungs or other organs—and causing a relapse. As viral respiratory infections like SARS-CoV-2 (the virus that causes COVID-19) are associated with inflammation, this may trigger processes that could cause cancer cells to spread. A rise in cancer death rates in the first two years of the pandemic led DeGregori and his colleagues to study the effects of the influenza virus and SARS-CoV-2 infections on breast cancer outcomes in mouse models. They determined that these infections reduced the dormancy of breast cancer cells in the lungs. The cancer cells multiplied within days of infection, leading to the expansion of metastatic cancer lesions within two weeks. Inflammatory pathways are implicated in this effect, the researchers found. "The study proves that the general phenomenon can also be observed in humans. Of course, the authors cannot prove that it is the same mechanism, as these are epidemiological data," said professor Carsten Watzl, Scientific Director of the Immunology Research Unit of the Leibniz Research Centre for Working Environment and Human Factors Dortmund. An image showing the awakening of dormant cancer cells. An image showing the awakening of dormant cancer cells. Bryan Johnson Analysis of molecules revealed that the awakening of dormant cancer cells is driven by a protein called interleukin-6 (IL-6), which immune cells release in response to infections or injuries. "The identification of IL-6 as a key mediator in arousing DCCs from dormancy suggests that using IL-6 inhibitors or other targeted immunotherapies might prevent or lessen the resurgence of metastasis following viral infection," said paper author and MECCC cell biologist Julio Aguirre-Ghiso said in a statement. The researchers also examined whether patients with cancer that tested positive for COVID-19 might have an increased risk of cancer-related death, analyzing data from the UK Biobank (4,837 participants, all cancer types) and Flatiron Health (36,845 patients with breast cancer) databases. They discovered an association between SARS-CoV-2 infection and risk of death in the Biobank group. Patients that tested positive SARS-CoV-2 showed a twofold increase in cancer-related death compared to those who were negative. In the Flatiron group, the infection was associated with an increase of more than 40 percent in the risk of metastatic disease in the lungs. It should be noted the new study focused on the period before COVID-19 vaccines were available. Although the studies were limited to those previously diagnosed with cancer, or mice that had dormant cells already when infected, DeGregori cautioned that the team, "couldn't rule out an effect on those with active cancer." Cell and molecular biologist John Alcorn of the University of Pittsburg told Newsweek, "This study does not address how bad of a COVID or flu infection is needed to trigger this type of response. Another prevention would be to have imaging done if you are a cancer patient in remission who gets a viral pneumonia. This could lead to early detection or resurgence and increased treatment options." DeGregori added: "Additional research and clinical studies will be needed for the development of interventions that could be applied during the infection, and we are actively working to develop such interventions." The researchers plan to extend their analyses, both in animal models and of clinical data, to other cancer types and areas of metastatic disease. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about breast cancer? Let us know via health@ Reference Chia, S. B., Johnson, B. J., Hu, J., Valença-Pereira, F., Chadeau-Hyam, M., Guntoro, F., Montgomery, H., Boorgula, M. P., Sreekanth, V., Goodspeed, A., Davenport, B., De Dominici, M., Zaberezhnyy, V., Schleicher, W. E., Gao, D., Cadar, A. N., Petriz-Otaño, L., Papanicolaou, M., Beheshti, A., Baylin, S. B., ... DeGregori, J. (2025). Respiratory viral infections awaken metastatic breast cancer cells in lungs. Nature.
